olvanil and Inflammation

The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials. This may have occurred because AEA also activates transient receptor potential vanilloid type 1 (TRPV1), which contributes to pain development. Therefore, we investigated the effectiveness of the dual FAAH-TRPV1 blocker OMDM-198 in an MIA-model of osteoarthritic pain. We first investigated the MIA-induced model of OA by (1) characterizing the pain phenotype and degenerative changes within the joint using X-ray microtomography and (2) evaluating nerve injury and inflammation marker (ATF-3 and IL-6) expression in the lumbar dorsal root ganglia of osteoarthritic rats and differences in gene and protein expression of the cannabinoid CB1 receptors FAAH and TRPV1. Furthermore, we compared OMDM-198 with compounds acting exclusively on FAAH or TRPV1. Osteoarthritis was accompanied by the fragmentation of bone microstructure and destroyed cartilage. An increase of the mRNA levels of ATF3 and IL-6 and an upregulation of AEA receptors and FAAH in the dorsal root ganglia were observed. OMDM-198 showed antihyperalgesic effects in the OA model, which were comparable with those of a selective TRPV1 antagonist, SB-366,791, and a selective FAAH inhibitor, URB-597. The effect of OMDM-198 was attenuated by the CB1 receptor antagonist, AM-251, and by the nonpungent TRPV1 agonist, olvanil, suggesting its action as an "indirect" CB1 agonist and TRPV1 antagonist. These results suggest an innovative strategy for the treatment of OA, which may yield more satisfactory results than those obtained so far with selective FAAH inhibitors in human OA.

Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides; Capsaicin; Carbamates; Cinnamates; Disease Models, Animal; Endocannabinoids; Ganglia, Spinal; Gene Expression; Hyperalgesia; Inflammation; Interleukin-6; Lumbar Vertebrae; Male; Osteoarthritis; Pain; Pain Management; Pain Measurement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; TRPV Cation Channels

Systemic capsaicin and an analogue, olvanil (NE-19550, 4-hydroxy-3-methoxyphenyl methyl-9Z-octadecenamide), were tested for antinociceptive activity in a model of persistent pain produced by the subcutaneous injection of formalin into the rodent hind paw. Formalin induced a biphasic nociceptive response in mice and rats which was measured (a) by the time spent licking the injected paw in mice and (b) by making electrophysiological recordings of single nociceptive neurone discharges in L1-L3 of the spinal dorsal horn of halothane-anaesthetised rats. In mice the initial phase of the response was reduced by systemic administration of morphine, capsaicin and olvanil but not by indomethacin. The second, more prolonged, inflammatory phase of the response was reduced by each agent. In rats, similar concentrations of capsaicin and olvanil reduced both the first and second components of the formalin response. These data show that capsaicin and a non-pungent analogue, olvanil, are efficacious antinociceptive agents in a model of prolonged chemical nociception induced by formalin. Their activity compares favourably with that of morphine and appears superior to that of indomethacin.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Electrophysiology; Foot; Formaldehyde; Indomethacin; Inflammation; Mice; Morphine; Neurons; Pain; Spinal Cord

We have evaluated the properties of a new class of anti-inflammatory agents derived from capsaicin, using the analogs NE-19550 (N-vanillyloleamide) and NE-28345 (N-oleyl-homovanillamide) as examples. This class displayed an atypical profile in the assays utilized, including 1) anti-edema and antileukocyte migration activity in the rat carrageenan pleurisy assay without suppression of pleural prostanoid synthesis, 2) blockade of human platelet aggregation induced by arachidonate or PAF but not that induced by the PGH2 analog U-46619, without equivalent inhibition in vitro of mammalian cyclooxygenase or thromboxane synthetase preparations, 3) greater potency and efficacy in the rat implanted sponge assay than in the adjuvant arthritis assay, without inhibition of LTB4 or 15-HETE synthesis in vitro, 4) stronger topical activity in the mouse croton oil inflamed ear assay than the guinea pig UV erythema assay, and 5) oral activity in the rat carrageenan paw edema assay and mouse phenylquinone abdominal constriction rest combined with failure to induce gastric erosion in rats at therapeutic doses. We conclude that NE-19550 and NE-28345 do not act like conventional NSAIDs via suppression of arachidonic acid metabolism.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arachidonic Acids; Arthritis, Experimental; Capsaicin; Carrageenan; Cell Movement; Edema; Guinea Pigs; Inflammation; Leukocytes; Male; Mice; Otitis; Platelet Aggregation Inhibitors; Pleurisy; Rats; Rats, Inbred Strains; Vanillic Acid